Abstract
An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain. The revised recommendations presented here give guidance on the use of morphine and the alternative strong opioid analgesics which have been introduced in many parts of the world in recent years. Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N and Ford I (1998) Randomised double blind crossover trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 16: 3222–3229
Chrubasik J, Wust H, Friedrich G and Geller E (1988) Absorption and bioavailability of nebulized morphine. Br J Anaesth 61: 228–230
Collins SL, Faura CC, Moore A and McQuay HJ (1998) Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 16: 388–402
De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V and Ripamonti C (1996) Clinical experience with oral methadone administration and the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14: 2836–2842
de Stoutz ND, Bruera E and Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378–384
Dover SB (1987) Syringe driver in terminal care. BMJ 294: 553–555
Eisenach JC, DuPen S, Dubois M, Miguel R and Allin D (1995) Epidural clonidine analgesia for intractable cancer pain. Pain 61: 391–399
Expert Working Group of the European Association for Palliative Care (1996) Morphine in cancer pain: modes of administration. BMJ 312: 823–826
Expert Working Group of the Research Network of the European Association for Palliative Care Strategies to relieve the adverse effects of oral morphine. J Clin Oncol, in press
Glare PA and Walsh TD (1991) Clinical pharmacokinetics of morphine. Ther Drug Monit 13: 1–23
Gourlay GK, Cherry D, Onley MM, Tordoff SG, Conn DA, Hood GM and Plummer JL (1997) Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 69: 295–302
Hanks GW (1990). Controlled release morphine tablets in chronic cancer pain: a review of controlled clinical trials. In: Benedetti C, Chapman CR, Giron G (eds). Opioid Analgesia. Recent Advances in Systemic Administration (Advances in Pain Research and Therapy 14) pp 269–274, New York: Raven Press
Hanks GW (1991) Opioid responsive and opioid-non-responsive pain in cancer. Br Med Bull 47: 718–731
Hanks GW and Hawkins C (2000). Agreeing a gold standard in the management of cancer pain: the role of opioids, In: Hillier R, Finlay I, Welsh J, Miles A (eds). UK Key Advances in Clinical Practice Series 2000. The Effective Management of Cancer Pain pp 57–75, London: Aesculapius Medical Press
Hanks GW, Hoskin PJ, Aherne GW, Turner P and Poulain P (1987) Explanation for potency of oral morphine on repeated dosage?. Lancet ii: 723–725
Hoskin PJ, Hanks GW, Aherne GW, Chapman D, Littleton P and Filshie J (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 27: 499–505
Houde RW (1986) Clinical analgesic studies of hydromorphone. In: Foley KM, Inturrisi CE (eds). Advances in pain research and therapy. Vol 8 pp 129–135, New York: Raven Press
Jadad AR and Browman GP (1995) The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274: 1870–1873
Kaiko RF (1988) The therapeutic equivalence of IM and PO administration of morphine – 1:3 or 1:6. J Palliat Care 4: 64–66
Kalso E and Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47: 639–664
Lasagna L (1965) Addicting drugs and medical practice: towards the elaboration of realistic goals and the eradication of myths, mirages and half-truths. In: Wilner DM, Kassebaum GG (eds) Narcotics. pp. 53–56, New York: McGraw
Lehmann KA and Zech D (1992) Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage 7: S8–S16
McQuay H (1999) Opioids in pain management. Lancet 353: 2229–2232
McQuay HJ and Moore RA (1997) Opioid problems, and morphine metabolism and excretion. In: Dickenson AH, Besson J-M (eds) Handbook of Experimental Pharmacology 130 pp 335–360, Berlin: Springer-Verlag
Megens A and Artois K (1998) Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 15: 253–257
Mercadante S (1999a) Pain treatment and outcomes for patients with advanced cancer who receive follow up care at home. Cancer 85: 1849–1858
Mercadante S (1999b) Problems of long term spinal opioid treatment in advanced cancer patients. Pain 79: 1–13
Moulin DE, Kreeft JH, Murray PN and Bouquillon AI (1991) Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 337: 465–468
Plummer JL, Gourlay GK, Cherry DA and Cousins MJ (1988) Estimation of methadone clearance: application in the management of cancer pain. Pain 33: 313–322
Portenoy RK and Hagan NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273–281
Portenoy RK, Payne R and Coluzzi P (1999) Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303–312
Regnard CFB and Badger C (1987) Opioids, sleep and the time of death. Palliat Med 1: 107–110
Ripamonti C and Bruera E (1991) Rectal, buccal and sublingual narcotics for the management of cancer pain. J Palliat Care 7: 30–35
Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A and De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol 16: 3216–3221
Säwe J (1986) High dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. (1986). Clin Pharmacokin 11: 87–106
Säwe J, Dahlström B and Rane A (1983) Steady state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 24: 537–542
Twycross RG (1984) Control of pain. J R Coll Physicians Lond 18: 32–39
Twycross RG (1988) The therapeutic equivalence of oral and subcutaneous/intramuscular morphine sulphate in cancer patients. J Palliat Care 4: 67–68
Twycross R (1994). Pain relief in advanced cancer, pp 261–266, Edinburgh: Churchill Livingstone
Vainio A, Ollila J, Matikainen E, Rosenberg P and Kalso E (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346: 667–670
World Health Organisation (1996). Cancer Pain Relief 2nd edition. WHO: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hanks, G., Conno, F., Cherny, N. et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84, 587–593 (2001). https://doi.org/10.1054/bjoc.2001.1680
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1680
Keywords
This article is cited by
-
The Role of Pharmacogenomics in Opioid Prescribing
Current Treatment Options in Oncology (2022)
-
Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction
Abdominal Radiology (2021)
-
Oxycodone in the Opioid Epidemic: High ‘Liking’, ‘Wanting’, and Abuse Liability
Cellular and Molecular Neurobiology (2021)
-
Understanding the Chameleonic Breakthrough Cancer Pain
Drugs (2021)
-
Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses
Supportive Care in Cancer (2020)
